A sore red eye with systemic involvement by Shalchi, Z et al.
A sore red eye with systemic involvement
Zaid Shalchi ophthalmology specialty registrar year 2 andMSc student13, Susan L Lightman professor
of clinical ophthalmology and consultant ophthalmologist 2 3, Charles D Pusey professor of medicine
and head of renal medicine 2 4, Simon R J Taylor National Institute for Health Research clinical
lecturer in ophthalmology 1 2 3
1Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK; 2Multidisciplinary Vasculitis Clinic, Imperial College Healthcare NHS Trust,
Hammersmith Hospital, London, UK; 3UCL Institute of Ophthalmology, London, UK; 4Faculty of Medicine, Imperial College London, Hammersmith
Hospital
A 20 year old man was referred to the eye clinic by his general
practitioner with a four week history of a sore red left eye (fig
1). Treatment for conjunctivitis had not resulted in improvement,
and he reported that his eye was increasingly painful. He had
experienced repeated nose bleeds over the past three months,
together with constant left sided nasal stuffiness. He had recently
felt generally unwell and had lost 4 kg. On examination, his
visual acuity was 6/9 in both eyes. His vital signs were stable,
but urinalysis showed blood+++ and protein+.
Fig 1 The patient’s eye at presentation
Questions
1 What abnormalities are seen in the photograph?
2 What is the most likely underlying diagnosis given his
extraocular symptoms?
3 What further investigations are appropriate?
4 What is the pathophysiology of this condition?
5 What treatment would you recommend and what is the
prognosis?
Answers
1 What abnormalities are seen in the
photograph?
Short answer
The abnormality is in the sclera—the tough white outer coat of
the globe. A large area of necrotic sclera can be seen extending
around the superonasal side of the cornea.
Long answer
The abnormality is in the sclera—the tough white outer coat of
the globe. A large area of necrotic sclera can be seen extending
around the superonasal side of the cornea. Non-necrotising
scleritis presents as a red sore eye, but the white avascular area
of sclera seen here is indicative of necrotising disease.
2What is themost likely underlying diagnosis
given his extraocular symptoms?
Short answer
Necrotising scleritis can be associated with several connective
tissue disorders, the most common being Wegener’s
granulomatosis. The combination of necrotising scleritis, upper
airway symptoms, and constitutional symptoms strongly suggest
this as the diagnosis.
Long answer
Necrotising scleritis is associated with a medical disorder in
39-50% of cases, particularly connective tissue disease or
systemic vasculitis.1 2 History taking, examination, and
investigations should centre on a differential diagnosis of
systemic lupus erythematosus; rheumatoid arthritis; Crohn’s
disease; or the antineutrophil cytoplasmic antibody (ANCA)
associated vasculitides, including Wegener’s granulomatosis.
Wegener’s granulomatosis is the most common cause, and the
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combination of necrotising scleritis, upper airway symptoms,
and constitutional symptoms strongly suggests this as the
diagnosis.3
3What further investigations are appropriate?
Short answer
The diagnosis of necrotising scleritis is clinical, but ifWegener’s
granulomatosis is suspected, serious renal involvement must be
urgently excluded by urinalysis with a dipstick. Radiographic
assessment of the respiratory system and formal evaluation for
renal disease are indicated. Antineutrophil cytoplasmic
antibodies (ANCAs) are usually positive in systemicWegener’s
granulomatosis but can be negative, particularly if the disease
is limited to the orbit.
Long answer
The diagnosis of necrotising scleritis is clinical, but because it
is often associated with systemic disease a thorough
investigation is essential. Patients should be investigated with
urine dipstick for blood and protein, as well as serum rheumatoid
factor, antinuclear antibodies, and ANCAs. White cell count,
C reactive protein concentration, and erythrocyte sedimentation
rate are useful to look for evidence of systemic inflammation.
If Wegener’s granulomatosis is suspected, it is important to
exclude serious renal involvement urgently. Radiographic
assessment of the respiratory system and evaluation for renal
disease are indicated. The ANCA test is usually positive in
systemic Wegener’s disease but can be negative, particularly if
disease is limited to the orbit.4 ANCAs may be present in other
conditions (such as ulcerative colitis, ankylosing spondylitis,
and Churg-Strauss syndrome), and a negative ANCA test does
not exclude a diagnosis of Wegener’s granulomatosis.4 Direct
immunofluorescence can distinguish different patterns of ANCA
staining, and cytoplasmic ANCA (cANCA) staining is classic,
whereas perinuclear ANCA (pANCA) staining is more
commonly a feature of microscopic polyangiitis. The
demonstration of antiproteinase 3 antibodies on ELISA (enzyme
linked immunosorbent assay) has a sensitivity of 91% and
specificity of 99% for active Wegener’s granulomatosis.3
A biopsy showing granulomatous inflammation and necrotic
vasculitis is the gold standard in disease diagnosis. This may
be obtained from an affected organ, such as the skin (in patients
with cutaneous vasculitis), kidney, lung, or orbit (in those with
granulomatous orbital inflammation). Although biopsy findings
are notoriously non-specific, renal biopsies may have a higher
diagnostic yield when performed by a skilled clinician and
reviewed by an experienced histopathologist.
The modified American College of Rheumatology criteria for
the diagnosis ofWegener’s granulomatosis (1990) stipulate that
at least two of the following be present: nasal or oral
inflammation, abnormal chest radiograph, active urine sediment
(microhaematuria or red cell casts), and positive biopsy. Some
have argued that a positive ANCA titre be included as a fifth
criterion.5
4 What is the pathophysiology of this
condition?
Short answer
Wegener’s granulomatosis is an autoimmune systemic vasculitis,
which commonly affects small and medium sized vessels. The
precise causes are not known, and it belongs to a larger group
of vasculitides in which disease is strongly associated with
ANCAs, including Churg-Strauss syndrome and microscopic
polyangiitis.
Long answer
Wegener’s granulomatosis is a rare disease. Its prevalence is
5-16 per 100 000 in northern Europe6 and three per 100 000 in
the United States.7 The average age of onset is 40-55 years, but
it may present at any age. There is no sex bias. The condition
is more common in white people than in Afro-Caribbeans.
Wegener’s granulomatosis is an autoimmune disease
characterised by systemic vasculitis, which commonly affects
small and medium sized vessels, as well as by granuloma
formation. The precise causes are not known,8 and it belongs to
a larger group of vasculitides in which disease is strongly
associated with ANCAs, including Churg-Strauss syndrome
and microscopic polyangiitis.
ANCAs are present in 90-95% of patients with systemic
Wegener’s disease.9 ANCAs directed against serum proteinase
3 lead to neutrophil activation, with resultant release of reactive
oxygen species and proteolytic enzymes, which cause damage
to the vascular endothelium and result in vasculitis.10Activation
of the immune system leads to disease in small and medium
sized vessels and causes multiorgan disease. The condition
commonly affects the upper respiratory tract and lungs, as well
as the kidneys, where rapidly progressive glomerulonephritis
commonly leads to chronic renal failure if not treated quickly
and aggressively. Wegener’s granulomatosis can also cause
painful swollen joints and skin nodules on the elbows; less
commonly, it also affects the brain and peripheral nervous
system, heart, and gastrointestinal tract. The varied and
non-specific nature of the symptoms often leads to delayed
diagnosis.
5 What treatment would you recommend and
what is the prognosis?
Short answer
Wegener’s granulomatosis is life threatening and requires
aggressive immunosuppression; cyclophosphamide has
revolutionised themanagement of this previously fatal condition.
Once the diagnosis is confirmed, start patients on intravenous
infusions of cyclophosphamide and high dose oral prednisolone
(1-2 mg/kg/day). Treatment of the underlying condition leads
to rapid resolution of necrotising scleritis without the need for
local treatment, unless the globe has already perforated, in which
case emergency surgery may be needed. Most patients respond
well to treatment, and survival is about 95% at five years and
80% at 10 years.
Long answer
Wegener’s granulomatosis is life threatening and requires
aggressive immunosuppression; cyclophosphamide has
revolutionised the management of this previously fatal
condition.11 Once the diagnosis is confirmed, patients should
be started on intravenous infusions of cyclophosphamide and
high dose oral prednisolone (1-2 mg/kg/day). Treatment of the
underlying condition leads to rapid resolution of necrotising
scleritis without the need for local treatment, unless the globe
has already perforated, in which case emergency surgery may
be needed.
Patients treated with cyclophosphamide must be monitored for
serious treatment related toxicity, including bone marrow
suppression and haemorrhagic cystitis.12 Once remission is
induced, introduce less toxic drugs such as azathioprine or
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methotrexate instead.13 14 Taper steroids to 7.5 mg/day or less
and continue treatment for at least one year. Plasmapheresis is
effective in pulmonary haemorrhage secondary to Wegener’s
disease.15
Newer biological agents have also been evaluated, and the
RAVE (Rituximab in ANCA associated Vasculitis) study
compared the ability of rituximab plus corticosteroids versus
cyclophosphamide plus corticosteroids to induce remission in
patients with severe systemic Wegener’s disease.16 Rituximab
was as effective as cyclophosphamide in inducing remission
but more effective in treating relapsing disease. Rituximab is
also effective in the treatment of refractory ophthalmic disease.17
Untreated,Wegener’s granulomatosis is rapidly fatal as a result
of renal failure and pulmonary haemorrhage, with a median
survival of five months. The use of steroids helped increase
average survival to eight months, but it was the use of
cyclophosphamide in the 1970s that led to dramatic
improvements in prognosis. These days, most patients respond
well to treatment, and survival is about 95% at five years and
80% at 10 years.11 18Relapses are common and should be treated
aggressively. Long term complications include chronic renal
failure and hearing loss.
Patient outcome
Our patient was diagnosed with Wegener’s granulomatosis.
Pulmonary nodules were seen on chest radiography and he was
positive for ANCAs on direct immunofluorescence and for
antiproteinase 3 antibodies on ELISA.
He was started on 80 mg oral prednisolone daily; concurrent
infusions of cyclophosphamide were arranged in conjunction
with the renal physicians through our multidisciplinary vasculitis
clinic, which includes renal doctors; ophthalmologists; and ear,
nose, and throat surgeons.
His symptoms improved rapidly with treatment. His nose bleeds
and nasal congestion improved, and he rapidly regained some
weight and felt better systemically. The necrotising scleritis
resolved without compromise to his vision (fig 2).
Fig 2 The patient’s eye six months later
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